Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
Additionally, tirzepatide did not attenuate the reduction of sleeping metabolic rate or 24-h sedentary energy expenditure in comparison to baseline (though not significantly different than placebo), but significantly increased fat oxidation and decreased carbohydrate and protein oxidation as compared to placebo [57]
Here are some tips to help ensure you maximize the benefits: - Follow your doctors dosing and administration instructions precisely
Do GLP-1 drugs reduce inflammation in the brain
35,104,116 On August 22, 2022, Novo Nordisk announced the primary results of the Phase II clinical trial for the dual-action compound CagriSema, which demonstrated effective blood sugar reduction and weight loss
The FLOW trial, a double-blind, placebo-controlled study examining renal outcomes in patients with type 2 diabetes and chronic kidney disease, demonstrated that semaglutide reduced the progression of kidney disease by 24% compared to placebo
